TC
NAVB

TFS Capital’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

TFS Capital’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-24,491
Closed -$789K – 1130
2015
Q2 		$789K Sell
24,491
-4,323
-15% -$126K 0.08% 398
2015
Q1 		$916K Buy
+28,814
New +$975K 0.09% 376
2014
Q4 		– Sell
-1,367
Closed -$36K – 1250
2014
Q3 		$36K Sell
1,367
-5,926
-81% -$157K ﹤0.01% 1007
2014
Q2 		$216K Sell
7,293
-7,450
-51% -$241K 0.02% 924
2014
Q1 		$545K Sell
14,743
-6,161
-29% -$234K 0.04% 697
2013
Q4 		$865K Buy
+20,904
New +$818K 0.04% 611

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TFS Capital's NAVB Position: Q3 2015 in Review

TFS Capital sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2015, closing a stake of 24,491 shares — an estimated $789K sold.

TFS Capital first reported a position in NAVB in Q4 2013 and held it in 6 quarters. The position peaked at $916K in Q1 2015. 81 funds tracked by Wall St. Rank hold NAVB as of Q3 2015.

  • TFS Capital reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2015 after selling out during the quarter.
  • TFS Capital sold 24,491 Navidea Biopharmaceuticals Inc. shares in Q3 2015, an estimated $789K.
  • TFS Capital first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2013 and held it in 6 quarters.
  • TFS Capital's Navidea Biopharmaceuticals Inc. position peaked at $916K in Q1 2015.
  • 81 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2015.

Based on TFS Capital's 13F filing for Q3 2015, filed 3 Nov 2015.